The first DMTs approved for relapsing-remitting MS (RR-MS) prophylaxis were the interferons-beta (IFNβ) and glatiramer acetate (GA), which remain first-line drugs, followed by other agents like natalizumab, mitoxantrone, and fingolimod, assigned as second-line treatments. Here, IFNB1 is linked to myeloid sarcoma.